Longeveron to Present at Virtual Life Sciences Investor Forum on June 20, 2024

MIAMI, June 17, 2024 — Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company specializing in regenerative medicine, has announced its participation in the upcoming Virtual Life Sciences Investor Forum scheduled for June 20, 2024.

The company's presentation will be available through a webcast, which can be accessed via the “Events and Presentations” section on Longeveron's website. For those unable to attend the live session, a replay will be accessible on the company's website for 90 days post-conference.

Longeveron Inc. is dedicated to developing regenerative medicinal therapies aimed at addressing significant unmet medical needs. Its primary investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Lomecel-B™ exhibits multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory properties, and capabilities for tissue repair and healing. These mechanisms make it a promising candidate for a wide array of disease treatments.

Longeveron is currently focusing its efforts on three main pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. The Lomecel-B™ HLHS program has notably received three significant designations from the U.S. FDA: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation, highlighting its potential importance and urgency in treating this condition.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!